JP2015505303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505303A5 JP2015505303A5 JP2014546471A JP2014546471A JP2015505303A5 JP 2015505303 A5 JP2015505303 A5 JP 2015505303A5 JP 2014546471 A JP2014546471 A JP 2014546471A JP 2014546471 A JP2014546471 A JP 2014546471A JP 2015505303 A5 JP2015505303 A5 JP 2015505303A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- pharmaceutical composition
- lipocalin mutein
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 35
- 102000019298 Lipocalin Human genes 0.000 claims 17
- 108050006654 Lipocalin Proteins 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 8
- 102000003816 Interleukin-13 Human genes 0.000 claims 7
- 108090000176 Interleukin-13 Proteins 0.000 claims 7
- 102000004388 Interleukin-4 Human genes 0.000 claims 7
- 108090000978 Interleukin-4 Proteins 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000003204 osmotic effect Effects 0.000 claims 4
- 101710169536 Interleukin-4 receptor subunit alpha Proteins 0.000 claims 3
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 3
- 239000000443 aerosol Substances 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 2
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010001881 Alveolar proteinosis Diseases 0.000 claims 2
- 101150020847 CCL11 gene Proteins 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 102100023688 Eotaxin Human genes 0.000 claims 2
- 101710139422 Eotaxin Proteins 0.000 claims 2
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims 2
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 230000009285 allergic inflammation Effects 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000019207 human interleukin-13 Human genes 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102000002090 Fibronectin type III Human genes 0.000 claims 1
- 108050009401 Fibronectin type III Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 102000004557 Interleukin-18 Receptors Human genes 0.000 claims 1
- 108010017537 Interleukin-18 Receptors Proteins 0.000 claims 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims 1
- 101710195550 Interleukin-23 receptor Proteins 0.000 claims 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 1
- 206010054949 Metaplasia Diseases 0.000 claims 1
- 101001033311 Mus musculus Interleukin-4 receptor subunit alpha Proteins 0.000 claims 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000037883 airway inflammation Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007783 downstream signaling Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000005714 functional activity Effects 0.000 claims 1
- 210000002175 goblet cell Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 241001515942 marmosets Species 0.000 claims 1
- 230000015689 metaplastic ossification Effects 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 230000003843 mucus production Effects 0.000 claims 1
- 238000002663 nebulization Methods 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000003489 pulmonary alveolar proteinosis Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000029069 type 2 immune response Effects 0.000 claims 1
- 102000042286 type I cytokine receptor family Human genes 0.000 claims 1
- 108091052247 type I cytokine receptor family Proteins 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570018P | 2011-12-13 | 2011-12-13 | |
| US61/570,018 | 2011-12-13 | ||
| PCT/EP2012/075146 WO2013087660A1 (en) | 2011-12-13 | 2012-12-12 | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067615A Division JP6725447B2 (ja) | 2011-12-13 | 2017-03-30 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505303A JP2015505303A (ja) | 2015-02-19 |
| JP2015505303A5 true JP2015505303A5 (enExample) | 2016-02-04 |
| JP6163162B2 JP6163162B2 (ja) | 2017-07-12 |
Family
ID=47552959
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546471A Expired - Fee Related JP6163162B2 (ja) | 2011-12-13 | 2012-12-12 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2017067615A Expired - Fee Related JP6725447B2 (ja) | 2011-12-13 | 2017-03-30 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2019062186A Expired - Fee Related JP6889201B2 (ja) | 2011-12-13 | 2019-03-28 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2020092168A Pending JP2020164532A (ja) | 2011-12-13 | 2020-05-27 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2022049676A Active JP7441589B2 (ja) | 2011-12-13 | 2022-03-25 | Ｉｌ－４および／またはｉｌ－１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067615A Expired - Fee Related JP6725447B2 (ja) | 2011-12-13 | 2017-03-30 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2019062186A Expired - Fee Related JP6889201B2 (ja) | 2011-12-13 | 2019-03-28 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2020092168A Pending JP2020164532A (ja) | 2011-12-13 | 2020-05-27 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2022049676A Active JP7441589B2 (ja) | 2011-12-13 | 2022-03-25 | Ｉｌ－４および／またはｉｌ－１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9572863B2 (enExample) |
| EP (3) | EP2790719B1 (enExample) |
| JP (5) | JP6163162B2 (enExample) |
| CN (2) | CN103998053B9 (enExample) |
| AU (1) | AU2012350660B2 (enExample) |
| CA (1) | CA2858962C (enExample) |
| DK (2) | DK2790719T3 (enExample) |
| ES (2) | ES2710384T3 (enExample) |
| HU (2) | HUE042720T2 (enExample) |
| PL (2) | PL3453400T3 (enExample) |
| SG (2) | SG10201604566QA (enExample) |
| TR (1) | TR201901826T4 (enExample) |
| WO (1) | WO2013087660A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900297T1 (it) | 2010-06-08 | 2019-07-11 | Astrazeneca Ab | Muteine di lipocalina lacrimale che si legano a il-4 r alfa |
| SG10201604566QA (en) * | 2011-12-13 | 2016-07-28 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| CN113621050A (zh) * | 2014-05-22 | 2021-11-09 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
| CN108348573A (zh) | 2015-07-15 | 2018-07-31 | 皮里斯制药有限公司 | Lag-3特异性的新型蛋白 |
| CN113372446A (zh) * | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| MX2019008434A (es) | 2017-01-18 | 2019-11-11 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina con afinidad de unión por lag-3. |
| CA3059731A1 (en) | 2017-04-21 | 2018-10-25 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
| CN111518211B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
| WO2020200960A1 (en) | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| AU2021399151A1 (en) | 2020-12-18 | 2023-07-27 | Astrazeneca Ab | Lipocalin mutein dry powder formulation for treatment of asthma |
| CN115414467B (zh) * | 2022-10-14 | 2023-06-06 | 中国人民解放军陆军军医大学第二附属医院 | 载脂蛋白d在制备治疗脑出血药物中的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| PL192364B1 (pl) | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| DE10043509A1 (de) | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003233583A1 (en) * | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| RU2389796C2 (ru) | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| EP1996613B1 (en) | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| AU2007280398B2 (en) * | 2006-08-01 | 2012-05-10 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| EP2178547A4 (en) * | 2007-07-11 | 2011-02-16 | Aerovance Inc | PHARMACEUTICAL FORMULATION OF POLYPEPTIDE DRY POWDER AEROSOL AND PROCESS FOR PREPARING THE SAME |
| SMT201900297T1 (it) | 2010-06-08 | 2019-07-11 | Astrazeneca Ab | Muteine di lipocalina lacrimale che si legano a il-4 r alfa |
| SG10201604566QA (en) | 2011-12-13 | 2016-07-28 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
-
2012
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en not_active Ceased
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
- 2012-12-12 ES ES12813295T patent/ES2710384T3/es active Active
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/zh not_active Expired - Fee Related
- 2012-12-12 US US14/364,449 patent/US9572863B2/en not_active Expired - Fee Related
- 2012-12-12 PL PL18197286T patent/PL3453400T3/pl unknown
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/zh not_active Expired - Fee Related
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/tr unknown
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/ja not_active Expired - Fee Related
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/hu unknown
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/hu unknown
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/da active
- 2012-12-12 PL PL12813295T patent/PL2790719T3/pl unknown
- 2012-12-12 ES ES18197286T patent/ES2863410T3/es active Active
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en not_active Ceased
-
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
-
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
-
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/ja not_active Expired - Fee Related
- 2019-07-16 US US16/513,636 patent/US10857202B2/en not_active Expired - Fee Related
-
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/ja active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
-
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/ja active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505303A5 (enExample) | ||
| JP6889201B2 (ja) | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 | |
| JP7169693B2 (ja) | 呼吸器疾患の治療 | |
| CN108778316B (zh) | 糖皮质激素联合聚乙二醇修饰的白介素2治疗呼吸道疾病 | |
| RU2015144185A (ru) | Лечение заболеваний, опосредованных тh2, путем ингибирования бромодоменов | |
| Ohga et al. | The suppressive effects of YM-58483/BTP-2, a store-operated Ca2+ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo | |
| RU2013157398A (ru) | Композиция | |
| KR102875179B1 (ko) | 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물 | |
| CN115697301A (zh) | 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法 | |
| CN101883566B (zh) | 用于治疗或预防涉及组胺h4受体的病症的美喹他嗪 | |
| WO2014046624A1 (en) | A method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway | |
| Baradia et al. | Inhalation therapy to treat pulmonary arterial hypertension | |
| Syabbalo | The role of airway remodeling in the pathogenesis and treatment of chronic obstructive pulmonary disease | |
| AU2020287832A1 (en) | Prevention and treatment of pulmonary inflammation and inflammatory remodeling using R-enantiomer beta-2-agonists for reduced adverse effects | |
| HK40058742B (zh) | 呼吸性疾病的治疗 | |
| Nishihara et al. | 155 Omalizumab Improves Asthma but not Nasal Symptoms in Japanese Patients With Severe Allergic Asthma and Rhinitis | |
| Park et al. | 153 Effect of Simvastatin on Transforming Growth Factor BETA-1-Induced Myofibroblast Differentiation and Collagen Production in Nasal Polyp-Derived Fibroblasts | |
| Berger et al. | 154 A 26-Week Study Evaluating the Safety and Efficacy of Ciclesonide Hydrofluoralkane Nasal Aerosol in Subjects With Perennial Allergic Rhinitis | |
| HK40004111A (en) | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors | |
| HK40001660A (en) | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors | |
| HK40001660B (en) | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |